Risk prediction models: II. External validation, model updating, and impact assessment

被引:961
作者
Moons, Karel G. M. [1 ]
Kengne, Andre Pascal [1 ,2 ,3 ,4 ]
Grobbee, Diederick E. [1 ]
Royston, Patrick [5 ]
Vergouwe, Yvonne [1 ]
Altman, Douglas G. [6 ]
Woodward, Mark [2 ,7 ]
机构
[1] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
[2] Univ Sydney, George Inst Global Hlth, Div Cardiovasc, Sydney, NSW 2006, Australia
[3] S African MRC, NCRP Cardiovasc & Metab Dis, Cape Town, South Africa
[4] Univ Cape Town, ZA-7925 Cape Town, South Africa
[5] MRC Clin Trials Unit, London, England
[6] Univ Oxford, Ctr Stat Med, Oxford, England
[7] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA
关键词
CARDIOVASCULAR-DISEASE RISK; CORONARY-HEART-DISEASE; PRIMARY-CARE; CLINICAL-PRACTICE; CONTROLLED-TRIAL; SAMPLE; RULES; PROGNOSIS; DESIGN;
D O I
10.1136/heartjnl-2011-301247
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Clinical prediction models are increasingly used to complement clinical reasoning and decision-making in modern medicine, in general, and in the cardiovascular domain, in particular. To these ends, developed models first and foremost need to provide accurate and (internally and externally) validated estimates of probabilities of specific health conditions or outcomes in the targeted individuals. Subsequently, the adoption of such models by professionals must guide their decision-making, and improve patient outcomes and the cost-effectiveness of care. In the first paper of this series of two companion papers, issues relating to prediction model development, their internal validation, and estimating the added value of a new (bio)marker to existing predictors were discussed. In this second paper, an overview is provided of the consecutive steps for the assessment of the model's predictive performance in new individuals (external validation studies), how to adjust or update existing models to local circumstances or with new predictors, and how to investigate the impact of the uptake of prediction models on clinical decision-making and patient outcomes (impact studies). Each step is illustrated with empirical examples from the cardiovascular field.
引用
收藏
页码:691 / 698
页数:8
相关论文
共 50 条
[1]
Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO
[2]
2-X
[3]
Prognosis and prognostic research: validating a prognostic model [J].
Altman, Douglas G. ;
Vergouwe, Yvonne ;
Royston, Patrick ;
Moons, Karel G. M. .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 :1432-1435
[4]
CARDIOVASCULAR-DISEASE RISK PROFILES [J].
ANDERSON, KM ;
ODELL, PM ;
WILSON, PWF ;
KANNEL, WB .
AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298
[5]
[Anonymous], BREAST CANCER TRANSL
[6]
[Anonymous], HEART
[7]
Brown CA., 2006, BMC MED RES METHODOL, V6, P54, DOI DOI 10.1186/1471-2288-6-54
[8]
Coleman RL, 2005, DIABETES, V54, pA172
[9]
Systematic review of prognostic models in patients with acute stroke [J].
Counsell, C ;
Dennis, M .
CEREBROVASCULAR DISEASES, 2001, 12 (03) :159-170
[10]
Prediction Models for Prolonged Intensive Care Unit Stay After Cardiac Surgery Systematic Review and Validation Study [J].
Ettema, Roelof G. A. ;
Peelen, Linda M. ;
Schuurmans, Marieke J. ;
Nierich, Arno P. ;
Kalkman, Cor J. ;
Moons, Karel G. M. .
CIRCULATION, 2010, 122 (07) :682-U16